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Quinoline derivatives such as chloroquine and primaquine are widely used for the treatment of
malaria. These drugs are also used for the treatment of trypanosomiasis, and more recently for can-
cer therapy. However, molecular target(s) of these drugs remain unclear. In this study, we have iden-
tiﬁed human pyridoxal kinase as a binding protein of primaquine. Primaquine inhibited pyridoxal
kinases of malaria, trypanosome and human, while chloroquine inhibited only malaria pyridoxal
kinase. Thus, we have identiﬁed pyridoxal kinase as a possible target molecule of the antimalarial
drugs chloroquine and primaquine.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The World Health Organization estimates that there were more
than 200 million people infected with malaria parasites in 2012,
causing approximately 627,000 deaths worldwide. Quinoline
derivatives such as chloroquine and primaquine are widely used
as antimalarial agents as well as drugs for some infectious diseases
such as trypanosomiasis [1]. Recently, chloroquine has also been
used for the treatment of cancer because it inhibits autophagy,
an important cellular function for the survival of cells in subopti-
mal environments [2,3]. To date, aldehyde dehydrogenase and qui-
none reductase 2 have been reported to be candidate binding
proteins of the quinoline derivatives in human cells [4]. The
growth of malaria protozoans was affected by speciﬁc quinone
reductase 2 inhibitors quercetin and chrysin with IC50 values of
approximately 80 lM and 50 lM, respectively [4]. Growth of
malaria parasites was also affected by a speciﬁc aldehyde dehydro-
genase inhibitor, diethyl-aminobenzaldehyde, with an IC50 of
approximately 300 lM [4]. These results suggested that quinone
reductase 2 and aldehyde dehydrogenase could be the targets of
antimalarial effects of the quinoline derivatives. However, there
is still argument that other target molecules mediate theantimalarial effects since the effective concentrations of inhibitors
are relatively high and direct association of chloroquine and
primaquine with malaria quinone reductase and malaria aldehyde
dehydrogenase and inhibition of these malaria enzymes by the
quinoline derivatives have not been demonstrated. On the other
hand, it has also been reported that chloroquine binds to heme
and inhibits heme polymerase activity in the malaria protozoan,
which is critical for heme intoxication [5]. The inhibition of heme
polymerization might account for the mechanism of action of chlo-
roquine as an antimalarial agent, although the corresponding
enzyme mediating heme polymerization has not been identiﬁed.
Thus, to date, the molecular targets of chloroquine and primaquine
that block protozoan infection and/or autophagy are not fully
understood.
Pyridoxal 50-phosphate, named vitamin B6, is an important
coenzyme of more than 100 enzymes in mammalian cells [6].
Additionally, this coenzyme is also essential for protozoan para-
sites such as trypanosomes and malaria parasites [6]. Because pyr-
idoxal 50-phosphate does not enter the cell, there must be cellular
uptake of its precursors pyridoxal, pyridoxamine and pyridoxine
[7]. These precursors are ﬁrstly phosphorylated by pyridoxal
kinase to their corresponding 50-phosphate product i.e., pyridoxal
50-phosphate, pyridoxamine 50-phosphate and pyridoxine
50-phosphate [8]. Finally, pyridoxamine 50-phosphate and pyridox-
ine 50-phosphate are then converted into pyridoxal 50-phosphate
3674 T. Kimura et al. / FEBS Letters 588 (2014) 3673–3676by pyridoxal 50-phosphate synthase [8]. Thus, pyridoxal kinase
plays a critical role in vitamin B6 production in cells, and inhibitors
of protozoan pyridoxal kinase are considered attractive drug candi-
dates for the treatment of protozoan infectious diseases [9].
In this study, we identiﬁed, for the ﬁrst time, pyridoxal kinase in
human cells as a binding protein of primaquine. We characterized
the inhibitory activity of primaquine as well as chloroquine against
human pyridoxal kinase and compared it with the corresponding
inhibitory activity against malaria and trypanosome pyridoxal
kinases.150
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Fig. 1. Pyridoxal kinase was detected as a primaquine binding protein. Silver-
stained SDS–PAGE gel (A) and immunoblot probed with anti-human pyridoxal
kinase antibody (B) for analyzing eluates from the control and primaquine-linked
beads in the pull-down experiment (see Section 2 for details). In (A), quinone
reductase 2 and aldehyde dehydrogenase, determined by TOF-MS, are indicated in
addition to pyridoxal kinase.2. Materials and methods
2.1. Cell culture and materials
HeLa cells were grown in RPMI 1640 (Nacalai Tesque, Kyoto,
Japan) including 10% FBS (Gibco BRL, Grand Island, NY) and
100 units/ml penicillin and 100 lg/ml streptomycin (Nacalai
Tesque) at 37 C under an atmosphere of 5% CO2. Primaquine bis-
phosphate, and chloroquine diphosphate were purchased from
Sigma–Aldrich (Tokyo, Japan), and Nacalai Tesque, respectively.
Anti-human pyridoxal kinase antibody (SAB1402426) was
obtained from Sigma–Aldrich.
2.2. Primaquine–Sepharose pull-down experiment
Primaquine–Sepharose was prepared by coupling primaquine
to epoxy-activated Sepharose 6B (GE Healthcare, Tokyo, Japan)
according to the manufacturer’s instructions. HeLa cells were
homogenized by 10 strokes with a glass homogenizer in Buffer A
(50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 2 mM MgCl2, 1 mM
DTT, 0.3% Triton X-100), supplemented with 1  protease inhibitor
cocktail (#25955-11; Nacalai Tesque, Kyoto, Japan) and the result-
ing cell extract was then clariﬁed followed by ultracentrifugation
at 100,000g at 4 C for 1 h. The supernatant was mixed with pri-
maquine-Sepharose or streptomycin–Sepharose and the slurry was
gently mixed on a rotating wheel rotated at 4 C for 2 h. After three
washes with Buffer A supplemented with 0.5  protease inhibitor
cocktail, bound proteins were eluted with 2 mM primaquine in
Buffer A. Eluates were concentrated by chloroform–methanol pre-
cipitation and subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS–PAGE) and silver stained. Protein bands of
interest were analyzed by time-of-ﬂight mass spectrometry (TOF-
MS).
2.3. Cloning and expression of pyridoxal kinases
The human pyridoxal kinase gene was ampliﬁed from human
lung cDNA (Takara Bio, Shiga, Japan) by polymerase chain reaction
(PCR) and cloned into the BamHI and XhoI sites of the expression
vector pRSET-A (Invitrogen, Tokyo, Japan). Nucleotides of pyridoxal
kinase of Plasmodium vivax (P. vivax) (XM_001616125) and Trypan-
osoma cruzi (T. cruzi) (XM_805806) were synthesized as artiﬁcial
genes with sequence modiﬁcation optimized for Escherichia coli
(E. coli) expression by Funakoshi Company (Tokyo, Japan). Both
genes were cloned into the BamHI and XhoI sites of pRSET-A. These
histidine-tagged proteins were produced in E. coli BL21(DE3) and
puriﬁed with Ni–NTA agarose (Qiagen, Tokyo, Japan). The buffer
was then exchanged into a buffer (20 mM HEPES (pH 7.0), 100 mM
KCl and 1 mM dithiothreitol) by ultraﬁltration.
2.4. Pyridoxal kinase activity assay
Since monovalent cations are crucial for pyridoxal kinase activ-
ity [10], it was measured in either 40 mM Na+ or 100 mM K+depending on the enzyme; both conditions were used for human
pyridoxal kinase and the K+ buffer was used for pyridoxal kinases
from malaria and trypanosome. In most cases, pyridoxal kinase
activity was measured by the absorbance method essentially as
described [11], where generated pyridoxal 50-phosphate from pyr-
idoxal was measured by absorbance at 388 nm using an extinction
coefﬁcient of 4900 M1 cm1. The assay was performed at 30 C in
10 mMHEPES (pH 7.0), 100 mM KCl (or 40 mMNaCl), 1 mMMgCl2,
1 mM Mg-ATP, pyridoxal and pyridoxal kinase. Km and kcat values
were calculated from Lineweaver–Burk plots [12]. Ki values were
estimated from Dixon plots [13]. Since primaquine greatly inter-
fered with the absorbance methodology, the ﬂuorescence method
was employed in the experiments using primaquine, essentially
as described previously [14] except the data were corrected by
division with the conversion rate in the presence of primaquine
(0.958, 0.875, 0.769, 0.688, and 0.647 for 100, 250, 500, 750 and
1000 lM primaquine, respectively) because primaquine itself
interfered the conversion from pyridoxal 50-phosphate to pyridoxic
acid 50-phosphate.
3. Results and discussion
3.1. Identiﬁcation of primaquine binding proteins in mammalian cells
To identify primaquine binding proteins in mammalian cells, a
pull-down experiment was performed using primaquine-coated
beads with HeLa cell extracts. As shown in Fig. 1A, several proteins
were speciﬁcally detected on the primaquine beads (lane 2), but
not on the control streptomycin-coated beads (lane 1). Proteins
that speciﬁcally bound to the primaquine beads included quinone
reductase 2 and aldehyde dehydrogenase, determined by TOF-MS,
both of which have previously been reported to be primaquine-
binding proteins [4]. These results indicated that the pull-down
procedure was successful. Using this methodology, we identiﬁed
pyridoxal kinase as a novel primaquine-binding protein. Immuno-
blotting analysis established that pyridoxal kinase did not bind to
either the streptomycin- or ethanolamine-coated beads (Fig. 1B),
conﬁrming the enzyme speciﬁcally binds primaquine.
3.2. Primaquine competitively inhibited human pyridoxal kinase
We ﬁrst generated and puriﬁed recombinant human histidine-
tagged pyridoxal kinase in E. coli (Fig. 2A, lane 1). Human pyridoxal
40
50
30
(kD)
1 2 3
(A) (B)
1/
V
(A
rb
itr
ar
y 
un
it)
Primaquine (µM)
(D)
(C)
Pyridoxal (µM) 
Py
ri
do
xa
lk
in
as
e 
ac
tiv
ity
 
w
ith
 p
ri
m
aq
ui
ne
  
(%
 o
f w
ith
ou
t p
ri
m
aq
ui
ne
 ) 
5
10
Py
ri
do
xa
lk
in
as
e 
ac
tiv
ity
 
(F
lu
or
es
ce
nc
e 
in
te
ns
ity
)
Time (min.)
20
80
Fig. 2. The effect of primaquine on human pyridoxal kinase activity. (A) Coomassie blue-stained SDS–PAGE gel of puriﬁed recombinant histidine-tagged pyridoxal kinases. (B)
Time-dependent pyridoxal kinase activity, measured by the ﬂuorescence method as described in Section 2, with 10 lM pyridoxal and 10 lg/ml enzyme in the absence (open
circles) and presence (closed circles) of 200 lM primaquine. The data shown are representative of three independent experiments, which all gave similar results. (C) Substrate
(i.e., pyridoxal) concentration-dependent pyridoxal kinase activity was analyzed using the same method as for (B) except with 5 lg/ml human pyridoxal kinase. The data
shown are expressed as mean ± S.D. of the ratio of the activity in the presence and absence of 200 lM primaquine from three independent experiments. (D) Dixon plot
analysis to determine the mode of inhibition of human pyridoxal kinase activity by primaquine. Pyridoxal kinase activity was measured in the presence of different
concentrations of primaquine using 1 lM and 5 lM pyridoxal with 2.5 lg/ml enzyme by the ﬂuorescence method as described in Section 2. The reaction velocity was
calculated based on the results at incubation periods of 5 min. The data shown are representative of four independent experiments, which all gave similar results.
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depending on the monovalent cation conditions used in the assay.
Km values for human pyridoxal kinase in both sodium and potas-
sium conditions were comparable to those reported previously
[10,15] (Table 1).
Next, we examined whether primaquine affected human pyri-
doxal kinase in the presence of sodium ions because it was not pos-
sible to use potassium ions in the assay, where substrate of
pyridoxal at concentrations >10 lM has been reported to inhibit
pyridoxal kinase activity [14]. As shown in Fig. 2B, primaquine at
200 lM apparently inhibited human pyridoxal kinase activity in
a time-dependent manner. Primaquine inhibited pyridoxal kinase
activity when the concentration of pyridoxal (i.e., substrate) was
low. However, inhibition was diminished when the concentration
of pyridoxal was increased (Fig. 2C). These data suggested that
the mode of inhibition is competitive. Dixon plot analysisTable 1
Properties of pyridoxal kinases.a
Pyridoxal kinase Human Human P. vivax T. cruzi
Monovalent cation Potassium Sodium Potassium Potassium
Km (lM) for pyridoxal 1.22 73.9 15.5 21.6
kcat (s1) 0.12 0.23 0.073 0.15
a Pyridoxal kinase activity was measured by the absorption method as described
in Section 2 in the presence of indicated monovalent cation and various concen-
trations of pyridoxal. The data shown are the representative of three independent
experiments with similar results.(Fig. 2D) conﬁrmed that the mode of inhibition of pyridoxal kinase
by primaquine was indeed ‘competitive’ with a Ki value of
57.2 ± 7.3 lM.
3.3. Primaquine also inhibited malaria and trypanosome pyridoxal
kinase
So far, no proteins have been identiﬁed as primaquine- or
chloroquine-binding protein in malaria (P. vivax) or trypanosome
(T. cruzi), both of which are the therapeutic target protozoans of
these agents. Here, we evaluated whether these drugs are effective
inhibitors of the pyridoxal kinase activity of malaria and trypano-
some parasites. Initially, we generated and puriﬁed recombinant
histidine-tagged forms of pyridoxal kinase from P. vivax and T. cruzi
(Fig. 2A). The pyridoxal kinase activity of each respective recombi-
nant enzyme was similar to that reported previously in the litera-
ture [9] (Table 1). As shown in Fig. 3A, primaquine apparently
inhibited pyridoxal kinase activity of both protozoan enzymes,
although the efﬁciency of inhibition was weaker compared with
that of human pyridoxal kinase.
The serum concentration of primaquine in human has been
reported to peak at 153 ng/ml (0.59 lM) after standard dosage of
the drug [16]. Thus, the serum concentration of primaquine is
much lower than the Ki values determined for the inhibition of pyr-
idoxal kinases of human as well as the target protozoans. As such,
it appears that pyridoxal kinase may not be a drug target of pri-
maquine. Nonetheless, if primaquine accumulates in the infected
protozoan, it might exert a killing effect on the parasite. Similarly,
accumulation of primaquine in human tissues could lead to various
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Fig. 3. Concentration-dependent inhibition of human, malaria and trypanosome
pyridoxal kinase by quinoline derivatives. The activities of human (closed triangle),
malaria (open circle) and trypanosome (closed circle) pyridoxal kinases were
measured in the presence of 5 lM pyridoxal as substrate. Enzyme activity was
determined in the presence of 5 lg/ml of the indicated enzyme and various
concentrations of primaquine using the ﬂuorescence method (A) or with 10 lg/ml
of indicated enzyme and various concentrations of chloroquine using the absor-
bance method (B). Refer to Section 2 for details. The data shown are means ± S.D. of
three independent experiments.
3676 T. Kimura et al. / FEBS Letters 588 (2014) 3673–3676adverse effects. Indeed, abdominal pain is sometimes reported
during primaquine therapy, which might be associated with
inhibition of vitamin B6 production from pyridoxal.
3.4. Chloroquine inhibited malaria, but not human or trypanosome
pyridoxal kinase
In the ﬁnal set of experiments, we examined whether chloro-
quine, another quinoline derivative used in the treatment of
malaria, inhibited pyridoxal kinases. Interestingly, chloroquine
inhibited only the malaria enzyme, but not the human or trypano-
some enzyme (Fig. 3B), although the efﬁciency of inhibition was
relatively low compared to the inhibition of human pyridoxal
kinase by primaquine. The antimalarial effect of chloroquine might
also be due to the inhibition of pyridoxal kinase. This result sug-
gests the possibility of developing potent antimalarial drugs by
speciﬁcally targeting malaria pyridoxal kinase.
In summary, we have identiﬁed pyridoxal kinases as molecules
affected by quinoline derivatives, chloroquine and primaquine,
used in the treatment of malaria. Our ﬁndings would provide use-
ful information concerning the mechanism of curative and/or
adverse side effects of these drugs. The results could also contrib-
ute to the development of more potent and safer antimalarial
agents in the future. Further experiments are required to conﬁrmthat pyridoxal kinase is the sole target molecule for exerting the
antimalarial effect of these compounds.
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